検索結果

maged, leading to progressive visual field loss, and if left untreated, can result in blindness. In Japan, glaucoma is reported to be the leading cause of visual impairment (including reduced vision a...

f Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has entered into...

お知らせ | 千寿製薬株式会社

MIEr for BeelineMED”（PDF） 2025年01月17日 Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF） 2024年11月26日 Launch and Distribution of ...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

Study Yuichi Hori,1 Tomoyuki Wada,2 Kazunori Omatsu2 1 Toho University Faculty of Medicine, Tokyo, Japan 2 Senju Pharmaceutical, Co., Ltd., Kobe, Hyogo, Japan 2025 SOT Annual Meeting and ToxExpo 開催日：...

Research and Development System | Research & Development | SENJU Pharmaceutica

cal package based on sophisticated regulatory strategies while expanding the development regions in Japan and globally, so that we can quickly commercialize the development compounds we create from th...